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Abstract: In this work, poloxamer (PL)-based binary hydrogels, composed of PL 407 and 
PL 188, were studied with regard to the physicochemical aspects of sol-gel transition and phar-
maceutical formulation issues such as dissolution-release profiles. In particular, we evaluated 
the cytotoxicity, genotoxicity, and in vivo pharmacological performance of PL 407 and PL 
407–PL 188 hydrogels containing tramadol (TR) to analyze its potential treatment of acute pain. 
Drug–micelle interaction studies showed the formation of PL 407–PL 188 binary systems and 
the drug partitioning into the micelles. Characterization of the sol-gel transition phase showed 
an increase on enthalpy variation values that were induced by the presence of TR hydrochloride 
within the PL 407 or PL 407–PL 188 systems. Hydrogel dissolution occurred rapidly, with 
approximately 30%–45% of the gel dissolved, reaching ~80%–90% up to 24 hours. For in vitro 
release assays, formulations followed the diffusion Higuchi model and lower K
rel
 values were 
observed for PL 407 (20%, K
rel
 =112.9±10.6 µg·h-1/2) and its binary systems PL 407–PL 188 
(25%–5% and 25%–10%, K
rel
 =80.8±6.1 and 103.4±8.3 µg·h-1/2, respectively) in relation to TR 
solution (K
rel
 =417.9±47.5 µg·h-1/2, P0.001). In addition, the reduced cytotoxicity (V79 fibro-
blasts and hepatocytes) and genotoxicity (V79 fibroblasts), as well as the prolonged analgesic 
effects (72 hours) pointed to PL-based hydrogels as a potential treatment, by subcutaneous 
injection, for acute pain.
Keywords: micelle, cytotoxicity, genotoxicity, analgesia
Introduction
Tramadol (TR; Figure 1) is a synthetic opioid analgesic chemically related to codeine 
and according to the World Health Organization is classified as a class II drug for 
the treatment of moderate intensity pain (eg, postoperative, oncologic, orofacial, neu-
ropathic, ischemic, musculoskeletal disorders, migraine, and osteoarthritis), either as 
monotherapy or in combination.1 Despite the fact that it is not a new opioid analgesic, 
TR has been rediscovered in the therapy of acute and chronic pain due to its particular 
mechanism of action (µ, δ, and κ opioid agonist and α2-adrenergic, 5-HT1A, and 
5-HT2A 5-HT3 antagonist),2,3 which evokes a low incidence of adverse effects when 
compared to classical opioids, such as morphine and fentanyl. However, TR use is 
associated with a short duration of analgesic effects.4 In this context, the development 
and pharmacological evaluation of drug delivery systems for TR would be of great 
interest for studying new formulations with potential clinical use in the treatment of 
acute and chronic pain. Among the several delivery systems reported in the literature, 
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poloxamer (PL)-based thermoreversible hydrogels have 
presented promising results in terms of improvement in the 
biopharmaceutical, pharmacodynamic, and pharmacokinetic 
properties of the incorporated drugs.
PLs (Pluronic®) are copolymers consisting of polyethyl-
ene oxide (PEO) and polyoxypropylene oxide (PPO) units 
arranged in a basic structure A–B–A or PEO–PPO–PEO 
type. Due to differences in the number of PPO and PEO 
units, PL monomers have the ability to self-assemble in 
micelles, presenting a hydrophobic core surrounded by a 
hydrophilic corona.5 At low temperatures, both PEO and 
PPO units are soluble in water. However, when the tem-
perature rises, the PPO units are dehydrated and aggregate 
(micellar core), while the hydrophilic PEO units (micellar 
corona) remain hydrated. Subsequently, these micelles 
are assembled in different supramolecular structures such 
as hexagonal, cubic-ordered phases forming the hydro-
gels’ organization phases. This reversible phenomenon is 
characterized by a temperature range of sol-gel transition 
(T
sol-gel
), since below this temperature, the systems remain 
as fluids and favor the development of injectable formula-
tions, but remain as semisolids close to the physiological 
temperature.6,7
In fact, these features associated with the biocompatibility 
of PL are essential for the development of delivery systems 
designed for pain treatment, since there is an influence of 
copolymer type and concentration, drug incorporation, and 
also temperature on biopharmaceutical properties (ie, dura-
tion of action and reduced uptake from the site of injection 
in direction to the blood stream). In addition, the use of PL 
with different hydrophilic–lipophilic balance (HLB), such as 
PL 407 and PL 188, as binary systems can be an interesting 
alternative to modulate the biopharmaceutical profile of these 
formulations.8–11
The use of PL has been reported in the literature spe-
cifically for pain treatment. Previous studies showed the 
increased permeation of lidocaine and ketoprofen incor-
porated into PL 407 liposomal hydrogels, across the swine 
dural membrane.12–14 Subsequently, other studies presented 
the preparation and characterization processes of PL 407 
hydrogels containing diclofenac,15 lidocaine, dibucaine, 
tetracaine,16–18 and bupivacaine19 as well as their pharmaco-
logical evaluations in animal models17,20,21 and humans.22,23 
However, these formulations were addressed for the use of a 
single type of PL. Moreover, there are no studies on PL-based 
in situ thermogelling hydrogel formulations containing TR 
for subcutaneous injection for the treatment of postoperative 
pain. Therefore, in this work we present the investigation of 
PL single-type and binary hydrogels composed of PL 407 
and PL 188 and also analyze the sol-gel transition process 
and pharmaceutical formulation issues such as dissolution-
release profiles, cytotoxicity, genotoxicity, and in vivo 
pharmacological evaluation.
Materials and methods
Materials
Poloxamer 407 (Pluronic® F127, molecular weight: 
12,600 Da) and Poloxamer 188 (Pluronic® F68, molecular 
weight: 8,400 Da) were purchased from Sigma-Aldrich Co. 
(St Louis, MO, USA). TR hydrochloride (attested purity 
of 98.5%) was donated by Cristália Produtos Químicos 
Farmacêuticos Ltda. (Itapira, Brazil). HEPES buffer and 
NaCl were purchased from Sigma-Aldrich Co. All other 
reagents were of analytical grade. Deionized water (Purelab 
Option-Q; ELGA LabWater, High Wycombe, UK) was used 
for all experiments.
hydrogels preparation
For hydrogels preparation, PL aqueous solutions (20 mM 
HEPES buffer with 154 mM NaCl, at pH 7.4) were pre-
pared according to the cold method.24 TR (20 mg·mL-1) was 
dispersed in different solutions containing PL 407 alone or 
in binary systems with PL 188 and were kept at 4°C under 
magnetic stirring (100 rpm). After dissolution, each formula-
tion was equilibrated overnight at 4°C. The PL concentra-
tions were selected in order to obtain a thermoreversible gel 
at minimum possible final concentration with a maximum 
final PL concentration of 35% (weight per weight [w/w]). 
All formulations are presented in Table 1.
Figure 1 chemical structure of tramadol.
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Physicochemical characterization: drug–
micelle interaction and sol-gel transition 
process
Dynamic light scattering was used to determine the polymeric 
micellar hydrodynamic diameter and the average distribution, 
in order to study the drug–micelle interaction and its influ-
ence on micellar assembly. Measurements were performed 
using a particle analyzer Zetasizer Nano ZS (Malvern, UK) 
at a fixed angle of 173° and temperatures of 25°C and 37°C. 
Micellar solutions (5% weight per volume PL final concentra-
tion) were prepared in 20 mM HEPES buffer with 154 mM 
NaCl, at pH 7.4, and were filtered using a polycarbonate 
membrane (pore 0.22 µm). The concentration of TR was 
20 mg·mL-1 for all PL solutions. Hydrodynamic micellar 
diameter measurements were determined at least three times 
for each sample.
For characterization of the hydrogels, differential scan-
ning calorimetry (DSC) analysis was performed to determine 
the temperature and enthalpy relative to the micellization pro-
cess and sol-gel phase transition temperature was determined 
using the tube inversion method. DSC experiments were 
performed with a TA Instruments (Q-200 DSC; New Castle, 
DE, USA) apparatus. Fifty milligrams of PL hydrogel (in the 
presence or absence of TR) were placed in sealed aluminum 
pans and samples were analyzed according to three succes-
sive thermal cycles of heating and cooling (0°C–50°C) at 
a heating–cooling rate of 5°C per minute with an empty pan 
as reference. Data were expressed in thermograms repre-
sented by heat flux (k·J·mol-1) versus temperature (°C).
For the tube inversion method, vials containing 1 g of 
hydrogels were incubated in a circulating water bath (Qui-
mis Aparelhos Científicos, Diadema, Brazil) at 0°C for 20 
minutes, to allow the samples to equilibrate thermally with 
their environment.18 After that, the temperature was increased 
(2°C/10 minutes) from 0°C to 60°C. At each increase, the 
samples were removed from the water bath (for a maximum 
of 30 seconds to prevent phase transition due to external 
temperature) and were inverted to observe the liquid/gel 
behavior. Samples were classified into three categories: 
1) liquid when the sample moved rapidly in the direction 
of gravity; 2) viscous liquid or soft gel when the sample 
moved slowly down in the direction of gravity; and 3) hard 
gel when the sample remained on the bottom of the vial. The 
temperature at which a sample was classified as hard gel was 
called the sol-gel point. All experiments were performed in 
triplicate.
Table 1 Micellization temperature (Tm), enthalpies (Δh°), sol-gel transition temperatures (Tsol-gel), release constant values (Krel), and 
correlation coefficients (Higuchi model) for PL 407 and binary system PL 407–PL 188 hydrogels
Formulations Formulations 
(PL w/w%)
Tm (°C) ΔH°(k⋅J⋅mol-1) Tsol-gel (°C) Krel (μg⋅h-1/2) R
2 (Higuchi 
model)
PL 407 20 15.1 52.4 30
25 12.8 49.6 26
30
35
10.6
9.8
54.4
52.1
24
22
PL 407–TR 20 14.7 47.9 30 112.9±10.6 0.980
25 12.4 50.8 26 95±5.6 0.991
30
35
10.2
9.6
51.4
50.3
24
22
82.1±3.6a***
81.3±4.2a***
0.986
0.993
PL 407–PL 188 20–2.5
20–5
20–10
25–2.5
12.8
12.1
11.4
11.5
23.9
22.7
20.8
21.0
30
34
36
26
25–5
25–10
11.9
11.2
19.9
19.8
28
30
PL 407–PL 188–TR 20–2.5
20–5
20–10
25–2.5
11.6
11.8
10.5
11.7
29.8
28.9
29.1
27.7
32
36
38
28
123.4±14.9
140.7±17.3
138.2±1.9
nd
0.981
0.990
0.996
nd
25–5
25–10
12.1
11.8
27.4
26.4
32
32
80.8±6.1b,c***,d*
103.4±8.3
0.999
0.981
Notes: Data expressed as mean ± sD (n=3). One-way aNOVa with post-hoc Tukey–Kramer test. ***P0.001; *P0.05. aPL 407 (30) or PL 407 (35) vs PL 407 (20); bPL 407–PL 
188 (25–5) vs PL 407 (20); cPL 407–PL 188 (25–5) vs PL 407–PL 188 (20–2.5; 20–5; 20–10); dPL 407–PL 188 (25–5) vs PL 407–PL 188 (25–10).
Abbreviations: aNOVa, analysis of variance; Pl, poloxamer; sD, standard deviation; Tr, tramadol; w/w, weight per weight.
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In vitro dissolution and release assays
Hydrogels samples were weighed (1 g) in plastic microtubes 
with a diameter of 1 cm and incubated in a water bath at 37°C 
for 12 hours. After that, 1 mL 20 mM HEPES buffer with 
154 mM NaCl (pH 7.4) was added to the samples, which were 
centrifuged at regular intervals from 30 minutes to 24 hours 
(13,000 g, 10 minutes). Afterward, the supernatant liquid 
was removed and the remaining hydrogel was weighed. The 
weight of the remaining hydrogel at each time point was 
expressed as a percentage of the original mass. All experi-
ments were performed in triplicate.
To avoid the direct dissolution of PL in the receptor medium, 
TR released was investigated to determine if the hydrogel is not 
expected to be quickly dissolved in physiological fluids, such as 
the subcutaneous fluid (since the interstitial volume medium is 
limited).5 A membrane diffusion model (Franz-type cells, 1.76 cm2 
permeation area, Automatized Microette Plus®; Hanson 
Research Corporation, Chatsworth, CA, USA) with artificial 
membrane (cellulose acetate sheets, molecular weight cut-off 
1,000 Da; Spectrum Laboratories, Inc., Rancho Dominguez, 
CA, USA) as a barrier was used to evaluate the in vitro 
release of TR from PL hydrogels. The donor compartment 
was filled with 1 g of the hydrogel formulations containing 
20 mg·mL-1 TR, while the receptor compartment was filled 
with 20 mM HEPES buffer with 154 mM NaCl buffer, 
pH 7.4, at 37°C, under constant magnetic stirring (350 rpm). 
A solution of 20 mg·mL-1 TR was used as control for total 
drug release. Aliquots from the receptor compartment were 
withdrawn (1 mL) and analyzed by ultraviolet–visible 
( UV–Vis) spectrophotometry (271 nm, y=0.03141+0.00983x, 
R2=0.99971, limit of quantification (LQ) =0.19 µg·mL-1; 
limit of detection (LD) =0.063 µg·mL-1, n=6, by an ana-
lytical curve previously obtained). Data were expressed as a 
percentage of TR released for each sample (n=6 replicates/
experiment).
animals
Male Wistar rats (250–300 g) and male Swiss mice (30–35 g) 
were obtained from the CEMIB-UNICAMP (Centro de 
Bioterismo, Universidade Estadual de Campinas, Campi-
nas, Brazil). Protocols were approved by the UNICAMP 
Institutional Animal Care and Use Committee (protocols 
2618-1/2012 and 2619-1/2012), which follows the recom-
mendations of the Guide for the Care and Use of Laboratory 
Animals. All animals were housed in standard cages and 
were maintained under a 12/12-hour controlled light–dark 
cycle at 23°C±2°C, with four animals per cage with food 
and water ad libitum.
cytotoxicity and genotoxicity assays
Cell viability tests were performed using fibroblasts (V79 cells 
from Chinese hamster lungs) and rat hepatocyte primary cell 
cultures. V79 cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal 
bovine serum with 100 UI·mL-1 penicillin and 100 µg·mL-1 
streptomycin sulfate (pH 7.2–7.4, humidified atmosphere at 
37°C and 5% CO
2
), seeded with 2×104 cells/well (96-well 
plates) and cultured for 48 hours. For primary cell cultures, 
hepatocytes were extracted from the rat liver using the 
perfusion technique, according to the method described 
previously25 with minor modifications. Initially, animals 
were anesthetized with alpha-chloralose (50 mg·kg-1) and 
urethane (1 g·kg-1) and the liver was perfused with Hank’s 
buffer for 20 minutes at 25 mL·min-1. After that, perfusion 
was maintained with a collagenase–Hank’s buffer (0.05% 
collagenase and 1 mM CaCl
2
) for 20 minutes at 15 mL·min-1 
flow rate. Then, the collected hepatocytes were suspended 
in DMEM supplemented with 50 UI·mL-1 streptomycin 
sulfate, 50 µg·mL-1 penicillin, 0.2% bovine serum albumin, 
0.1 IU·mL-1 bovine insulin, 1 µM dexamethasone, and 1% 
dimethyl sulfoxide in 10% fetal bovine serum. Cells were 
plated at 6×105 cells in 96-well culture plates.
Cells were incubated for 24 hours with TR (0.1–4 
mg·mL-1), PL 407 isolated or in a binary system PL 407–PL 
188 (0.1–40 mg·mL-1) before and after TR incorporation 
(n=6 replicates/concentration). After that, the number of 
viable cells was evaluated by a 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) reduction test and 
neutral red (NR) uptake.
The first method is based on the reduction of MTT to 
formazan by mitochondrial dehydrogenases. The formazan 
crystals were dissolved in a 1 N HCl–isopropyl alcohol mix-
ture (1:24 volume per volume) and shaken for 20 minutes. 
After that, the dye-containing solution was removed and 
the absorbance was determined at 570 nm.26 For the NR 
uptake test, the capability of viable cells to accumulate in 
lysosomes is measured. After cells were treated with dif-
ferent formulations, 0.2 mL of the 50 µg·mL-1 NR solution 
was added and incubated for 3 hours (in order to allow 
uptake of the dye by the lysosomes of viable cells). Subse-
quently, DMEM was removed and the cells were washed 
with a mixture of 1% formaldehyde and 1% CaCl
2
. Then, 
a solution of 1% acetic acid and 50% ethanol was added to 
remove the dye. After brief shaking, the absorbance was 
measured at 540 nm.27
Genotoxicity assays were also performed in V79 fibro-
blasts from Chinese hamster lungs by the comet assay single 
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cell gel electrophoresis (SCGE).28 The cells were exposed 
to the formulations at 4 mg·mL-1 TR concentration for 
1 hour. After exposure, 15 µL of treated cells were mixed 
in 120 µL agarose at a low melting point. The mixture 
was placed on a slide previously covered with agarose and 
was placed in lysing solution for 40 minutes. After this, 
the slides were transferred to a electrophoresis solution 
for 20 minutes before analysis was performed at 4°C for 
30 minutes (voltage: 25 V, amperage: 300 mA). Slides 
were then washed in neutralization solution for 5 minutes, 
and dried at room temperature. They were then hydrated, 
and the material contained in the slides was stained with 
silver nitrate for 30 minutes. The analyses were performed 
in an optical microscope and counting was carried out on 
three slides per treatment. The DNA damage was classi-
fied as class 0–4. Class 0 denotes no DNA damage and 
class 4 signifies the maximum DNA damage. The damage 
index (DI) was calculated by dividing the score of the slides 
by the number of cells present. The relative index of each 
treatment analyzed was obtained by dividing the DI relative 
to the different treatments (ie, formulations) per DI obtained 
for the control group (ie, no treated cells).
Pharmacological evaluation: in vivo 
analgesic effects
The analgesic effects were evaluated using the tail-flick 
test. First, the animal was placed in a horizontal acrylic 
restraint and fixed on an analgesimeter with a portion of 
the tail, 5 cm from its tip, exposed to heat from a projector 
lamp (55°C±1°C, 150 W), for the baseline measurement 
(ie, normal response to the noxious stimulus). The time for 
normal response (in seconds) was recorded by a control 
switch and a timer simultaneously activated. The timer stops 
immediately when the rat tail flicks. The formulations (TR 
or PL hydrogels) were injected subcutaneously (0.06 mL, at 
40 mg·kg-1 TR) on the dorsal surface of the cervical region. 
The evaluation was started 10 minutes after the injection of 
the formulations. The baseline values for each animal were 
considered as the time for normal response recovery (time 
for recovery or T
rec
). A 30-second cut-off period was used 
to avoid thermal injury. All experiments were performed by 
the same observer. Data were expressed as percentage of 
maximum possible effect (MPE%; Equation 1), duration of 
the analgesic effect (minutes), and area under the efficacy 
curve (AUEC) for each experimental group.
 MPE =  (test latency time – baseline/ 
 cut-off – baseline) ×100 (1)
statistical analysis
Data were expressed as percentage or mean ± standard devia-
tion (SD) and were analyzed by one-way analysis of variance 
(ANOVA) with the Tukey–Kramer post-hoc test using Graph 
Pad InStat (GraphPad Software, Inc., La Jolla, CA, USA) 
or Origin (v6.0; Microcal™ Software, Inc., Northampton, 
MA, USA) programs. Statistical differences were defined 
as P0.05.
Results and discussion
Physicochemical characterization: drug– 
micelle interaction and sol-gel phase 
transition studies
The hydrodynamic diameter determination was used as an 
important parameter for monitoring the formation of mixed 
micelles composed of PL 407 and PL 188 and also to study 
the micellar system before the supramolecular changes due 
to the sol-gel transition, in the presence or absence of TR.
Initially, no significant changes were observed on micel-
lar hydrodynamic diameter for PL 407 and PL 407–PL 188 
systems after TR incorporation. For the system composed of 
isolated PL 407, the micellar diameter was 30 nm at 25°C and 
represented 86% of the population analyzed against a small 
size population of 12 nm with 14% distribution. However, 
micellar diameters of ~20 nm (with a 98.5% mean distribu-
tion) were observed when the temperature was raised to 37°C. 
At this point, a transition was detected from a unimodal to 
a bimodal distribution, with differences on polydispersity 
values from 0.27 at 25°C to 0.19 at 37°C.
Similar results were also observed for PL binary sys-
tems PL 407–PL 188. However, larger mean hydrodynamic 
diameters (~50–75 nm) were detected for all copolymers 
proportions, which were associated with higher polydisper-
sity values (0.5–0.6) at both temperatures. The high mean 
hydrodynamic diameter and polydispersion values for binary 
system PL 407–PL 188 could be due to the formation of 
mixed micelles with more hydrated corona composed of 
copolymers presenting different ethylene oxide:propylene 
oxide (EO:PO) ratios: 3:1 and 5:1 for PL 407 and PL 188, 
respectively, when compared to PL 407 micelles.
The mean micellar hydrodynamic diameter determination 
can provide important information about the effects of changes 
in PL concentrations, micellar composition, the addition of TR 
and temperature on different formulations. The interactions 
between lidocaine, naproxen, salicylic acid, or pentobarbital 
with PL 407 micelles were also studied by other authors,29 
showing that the presence of charge on the incorporated 
molecule chemical structure influences the partitioning into 
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micelles. These observations may also be applied to our sys-
tems, since all formulations were prepared at physiological pH 
(7.4), below the pKa of TR (9.41). These conditions promote 
the presence of ionized TR species and their possible interac-
tion with the hydrated micellar corona region.
Table 1 presents the micellization temperatures (T
m
) and 
enthalpy variation (ΔH°) relative to the micellization process. 
In addition, the sol-gel transition temperature (T
sol-gel
) is also 
presented for all formulations. DSC analysis showed that the 
T
m
 were fairly similar for all formulations, at the same PL 
final concentration, especially for PL 407 hydrogels. How-
ever, T
m
 was decreased by ~5°C for the high PL 407 concen-
tration (30% w/w). On the other hand, for the binary system 
PL 407–PL 188, T
m
 variation was discrete (~0.5–1.6°C) when 
compared to PL 407 hydrogels.
For the PL 407 systems, high ΔH° values were observed 
according to the final copolymer concentration, even after 
TR incorporation. However, for the binary system PL 
407–PL 188, the enthalpy for micelle formation changed 
after the addition of PL 188, since ΔH° values were reduced 
at high PL 407 and PL 188 concentration. In addition, as 
observed after comparisons among the systems, there is a 
greater interference of the TR on self-assembly and micelle 
formation in the presence of PL 188, since ΔH° values were 
higher than those observed before TR incorporation.
In fact, the addition of more hydrophilic polymers (such 
as PL 188 with HLB =29) induces conformational changes in 
the micellar arrangement of the more hydrophobic copolymer 
PL 407 (HLB =22) as well as increases the hydration of the 
micellar corona (due to the larger number of EO units). This 
justifies the broader endothermic peak and the minor enthalpy 
variations observed during the micellization process for the 
binary systems.30–33 Moreover, comparisons among PL 407 
and its binary systems with PL 188 showed an increase in 
enthalpy variation values, possibly due to dehydration of 
units of the PPO micellar core that was induced by the pres-
ence of a hydrophilic drug such as TR hydrochloride into 
the PL 407–PL 188 systems.
After DSC studies, T
sol-gel
 was determined for all for-
mulations. Comparative analysis among the formulations 
composed of PL 407 showed lower T
sol-gel
 with higher copo-
lymer concentrations; this favors micelle formation and their 
self-assembly in gel structure. In addition, it was possible to 
compare the effect of the association between 30% PL 407 
(T
sol-gel
 =24°C) and PL 407–PL 188 binary systems at 20:10, 
25:5, or 25:10 (% w/w), showing that the presence of PL 188 
increased the T
sol-gel
 in a range of 8°C–12°C, when compared 
to PL 407 formulations.
Results from Table 1 show that the formulations with 
T
sol-gel
 values considered for subcutaneous use were 20% 
PL 407 (T
sol-gel
 =30°C), binary systems PL 407–PL 188 at 
20:2.5, 20:5, 20:10, 25:5, and 25:10 with T
sol-gel
 ranging 
from 32°C–38°C, after TR incorporation. For this reason, 
those formulations were selected for in vitro dissolution and 
release studies.
In vitro dissolution and release profiles
In order to investigate the mechanisms involved with TR in 
vitro release, membrane-free dissolution assays were carried 
out to simulate the contact between the hydrogels and the 
interstitial liquid after subcutaneous injection to determine 
whether the hydrogel dissolution associated with the PL unim-
ers solubilization could control the drug release.5 As observed 
in Figure 2A, in general, hydrogel dissolution occurred rapidly, 
with approximately 30%–45% of the gel dissolved until it 
reached ~80%–90% at 24 hours. This fact is possibly due to 
the relatively high aqueous solubility of PL 407 and PL 188 
(even considering the differences between HLB values for both 
copolymers used as base polymer for the formulations) and the 
low viscosity of the gel formed. However, these are important 
and relatively conserved features for the design of formula-
tions for parenteral administration (eg, subcutaneous route)7 
and must be considered for the future clinical application of 
the hydrogel on pain treatment, since it is interesting that the 
dissolution rate is fast enough to allow drug release to the site 
of action, especially for post- or intraoperative analgesia.
Figure 2B shows the TR release profiles from the different 
hydrogels. For the TR solution, the drug release was progres-
sive and reached total release at 4 hours, with 100% of the 
TR released. On the other hand, the formulation 20% PL 407 
and its binary systems with PL 188 (20%–2.5%; 20%–5%; 
20%–10%; 25%–5%; and 25%–10%) showed regular release 
profiles over 24 hours, with low release percentages for 
20% PL 407 (65.6%±1.4%); PL 407–PL 188, 20%:2.5% 
(69.1%±5.6%); PL 407–PL 188, 20%:5% (72.0%±6.2%); 
PL 407–PL 188, 20%:10% (72.6%±8.6%); PL 407–PL 188, 
25%:5% (45.1%±2.5%); and PL 407–PL 188, 25%:10% 
(63.9%±2.2%) when compared to TR solution (P0.001).
Release constant (K
rel
) values were then calculated using 
the Higuchi model, where the drug release rate is linear as 
a function of the root square of time, according to Fick’s 
laws of diffusion:34
 
Q t
t H
K= 1 2/
 
where Q is the drug concentration released against time, K
H
 is 
the release constant, and t is time.
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The calculated K
rel
 values are presented in Table 1. 
Statistical differences were observed for all formulations 
when compared to the TR solution (417.9±47.5 µg⋅h-1/2, 
P0.001), since hydrogels prolonged TR release for more 
than 24 hours with percentage release ranging from 40% 
to 60%.
The dissolution and release percentages were compared 
at 24 hours (Figure 2C) considering different mechanisms, 
such as possible hydrogel erosion by interstitial fluid at the 
administration site (subcutaneous route) and the diffusion of 
the drug through the hydrogels until reaching the systemic 
circulation.34,35 According to the lower K
rel
 values observed 
among the hydrogels, the formulations PL 407 (20%), PL 
407 (30%), PL 407 (35%) control groups and the binary 
systems PL 407–PL 188 (25%–5% and 25%–10%) were 
selected for in vivo pharmacological evaluation and further 
comparisons with the TR solution.
cytotoxicity and genotoxicity assays
Figure 3A and B show the cell viability percentage after treat-
ment with different TR concentrations from 0.1–4 mg⋅mL-1. 
In general, TR reduced the V79 cell viability percentages for 
the MTT reduction and NR uptake tests; more pronounced 
cytotoxic effects were observed for higher TR concentra-
tions (30% and 40% of viable cells with 2 mg⋅mL-1 TR and 
4 mg⋅mL-1 TR, respectively). On the other hand, low hepato-
cyte viability percentages were observed from 1–4 mg⋅mL-1 
(60%–55% of viable cells). These results were used in order 
to maintain the same TR concentrations for cell viability 
tests in the hydrogel formulations. The drug:PL (TR:PL) 
proportion was maintained as 1:10 (w/w%) or 1:200 molar 
ratio for all hydrogels into the cell culture wells for a final 
volume of 0.1 µL. Hydrogel cell viability curves presented 
similar profiles for V79 fibroblasts and hepatocytes for both 
the MTT and NR tests (Figure 4A and B).
Figure 2 In vitro dissolution and release profiles for TR from PL 407 and PL 407–PL 188 hydrogels (n=6/formulation).
Notes: (A) Membrane-free dissolution profiles, (B) time–release curves, and (C) dissolution-release relationships for hydrogels.
Abbreviations: Pl, poloxamer; Tr, tramadol.
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Figure 5 summarizes comparisons of the cytotoxic effects 
for all formulations with respect to the maximum TR con-
centration tested (4 mg⋅mL-1). PL hydrogels did not induce 
pronounced cytotoxic effects and hydrogels reduced the TR 
cytotoxic effects by 2.0- and 1.8-fold for V79 fibroblasts and 
hepatocytes, respectively (P0.001). In another analysis, 
the TR concentration was considered for genotoxicity stud-
ies. Results showed no significant genotoxic effects for all 
formulations tested (Figure 6).
In general, treatment of fibroblasts and hepatocytes with 
different concentrations of TR reduced the viability percent-
age determined by the MTT reduction and NR uptake tests. 
On the other hand, treatment of cells with PL 407 and the 
binary system PL 407–PL 188 showed that TR incorporation 
into PL hydrogels reduced the cytotoxic effects evoked by 
the drug. Further, the addition of PL 188 to formulations did 
not evoke significant cytotoxic effects in relation to the PL 
407 hydrogels. These results are in agreement with previ-
ous reports that showed a structural relationship between 
the copolymers and their cytotoxic effect, since lipophilic 
copolymers induce more pronounced fluidizing effects in cell 
membranes and particularly on the mitochondrial membrane 
(by PO unit insertion into the lipid bilayer) in different cell 
types such as endothelial cells from the blood–brain barrier 
vessels36 and lung carcinoma cells.37
Pharmacological evaluation: in vivo 
analgesic effects
Figure 7 presents the time curve of MPE% obtained after 
treatment with the TR solution and different hydrogels. In 
general, all hydrogels induced prolonged analgesic effects 
when compared to the TR solution. Moreover, the time 
Figure 3 cell viability percentages of (A) V79 fibroblasts and (B) hepatocytes after treatment with different concentrations of tramadol evaluated by MTT reduction and 
Nr uptake tests.
Note: n=6 experiments/concentration.
Abbreviations: MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Nr, neutral red; Tr, tramadol.
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Figure 4 Cell viability percentages of V79 fibroblasts evaluated by (A) MTT reduction test and (B) Nr uptake test for hepatocyte viability after treatment with different 
concentrations of Pl-based hydrogels.
Note: n=6 experiments/concentration.
Abbreviations: MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Nr, neutral red; Pl, poloxamer; Tr, tramadol.
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for hydrogel formation was less than 20 seconds (data not 
shown), suggesting that a depot hydrogel was readily formed 
after subcutaneous injection. Overall, the binary hydrogels 
(PL 407–PL 188) induced prolonged duration of analgesia 
(72 hours) and more pronounced AUEC when compared to 
the TR solution and 20% PL 407 (P0.001; Table 2).
TR can be administered by different routes, including 
oral, subcutaneous, epidural, intrathecal, intravenous, and 
intramuscular. After oral administration, TR is rapidly 
absorbed, with high plasma concentrations achieved at 
approximately 2 hours; the maximum analgesic effect is 
found between 1 and 4 hours after administration, but it 
persists for only 3–6 hours.1 However, because of the short 
duration of action, TR reinjections are required (orally or 
by continuous infusion) every 6 hours to obtain a prolonged 
analgesic effect.38 For this reason, the development of new 
pharmaceutical formulations that aim to control the drug 
release rate can reduce fluctuations in drug plasma levels and 
extended intervals between the daily administrations. This 
provides a significant advantage over commercially available 
immediate-release formulations. Therefore, the modified 
release formulations containing TR have been recommended 
for the treatment of both acute and chronic pain, and may be 
a possible solution with respect to inadequate analgesia and 
low patient compliance to the treatment.1,38
In this study, we proposed the use of thermosensitive 
hydrogel formulations for TR controlled release by subcutane-
ous route. In fact, subcutaneous TR has been demonstrated as 
an easy alternative to oral, intravenous, or intramuscular routes 
for postsurgical pain or local infiltrative analgesia.39–41 Several 
studies have reported the development of new TR formulations 
such as hydroxypropyl methylcellulose tablets containing semi-
permeable membranes42 and ethylcellulose microparticles43 for 
oral route. Other examples include chitosan-based adhesives 
and carbohydrate hydrogels for skin delivery44,45 and injectable 
polyhydroxybutyrate microspheres.38 However, none of them 
aimed to develop a hydrogel for subcutaneous use. Finally, 
even though this is a single-dose study, our results showed 
Figure 6 Relative DNA damage in V79 cells after treatment with PL-based hydrogels 
at 4 mg⋅ml-1.
Note: n=3 experiments/formulation.
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Figure 5 Cell viability percentages for PL 407 and PL 407–PL 188 formulations in fibroblasts (A) and hepatocyte (B).
Notes: Data expressed as mean ± sD (n=6). One-way aNOVa with post-hoc Tukey–Kramer test. ***P0.001. Tr (4 mg⋅ml-1) was maintained for all formulations. aall 
formulations vs Tr (solution), bPL 407–TR vs PL 407, and cPL 407–PL 188–TR vs PL 407–PL 188.
Abbreviations: aNOVa, analysis of variance; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Nr, neutral red; Pl, poloxamer; sD, standard deviation; 
Tr, tramadol.
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that the incorporation of TR into PL hydrogels promoted an 
increase in duration of analgesic effects with the possibility 
for reapplying every 48–72 hours at lower doses. This would 
significantly reduce systemic toxic effects and provides a 
hydrogel delivery system for subcutaneous TR.
Conclusion
Results obtained in this study allowed the design of PL-
based hydrogel preformulations for controlled release of 
TR by subcutaneous use for the potential future treatment 
of postoperative pain. Physicochemical characterization 
showed that the formation of binary systems composed 
of PL 407 and PL 188 alters the micellization and sol-gel 
transition processes. The dissolution/release relationships 
and analgesic activity assays demonstrated that PL 407 
and its binary systems with PL 188 are effective hydrogels 
for controlling and prolonging TR release for 48–72 hours 
after subcutaneous injection; this could reduce the number 
of administrations and possible adverse effects. Finally, 
the formulations tested here reduced the cytotoxicity 
compared to TR and no significant genotoxic effects were 
observed. These results demonstrate important features for 
the development of new drug carriers and their purpose as 
new therapeutic systems.
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